India Immune-Oncology Drugs Market, By Drug Type (Immune Checkpoint Inhibitors, Monoclonal Antibodies, and Cancer Vaccines) and By Cancer Type (Lung Cancer, Blood Cancer, Breast Cancer, Ovarian Cancer, Cervical Cancer, Colorectal Cancer, Stomach Cancer, Head & Neck Cancer, and Others) - Size, Share, Outlook, and Opportunity Analysis, 2018– 2026

  • Published On : May 2019 |
  • Pages : 162 Pages |
  • Format : CMI Insight PPT Format CMI Insight PDF Format

India Immune-Oncology Drugs Market – Insights

Immuno-oncology products come under biological therapeutic products. Immuno-oncology drugs are primarily used in therapeutic applications for treatment of various types of cancer such as lung cancer, breast cancer, colon cancer, and cervical cancer. Major players involved in the Indian immuno-oncology drugs market are focusing on research and development of new technologies and products. Several biopharmaceuticals and research organizations have been indigenously developing biologics in cancer treatment. For instance, researchers from Tata Centre for Technology and Design, IIT Bombay are currently working on developing indigenous CAR (chimeric antigen receptor) T-cell therapy, affordable for cancer patients in India.

India immune-oncology drugs market size was valued at US$ 172.8 million in 2018 and is expected to witness a CAGR of 13.1% over the forecast period (2018 – 2026).

India Immune-Oncology Drugs Market Share (%) Analysis, By Drug Type, 2018

India Immune-Oncology Drugs  | Coherent Market Insights

Source: Coherent Market Insights Analysis (2019)

Increasing Incidences of Cancer Cases and Introduction of Novel Immuno-Oncology Therapies is expected to Drive Growth of the India Immune-Oncology Drugs Market

Rising incidences of cancer in India is expected to boost the immuno-oncology drugs market during the forecast period. For instance, according to Indian Council of Medical Research (ICMR) - National Institute of Cancer Prevention and Research (NICPR), incidence of breast cancer is 25.8 per 100,000 women in 2018 and is expected to reach 35 per 100,000 women in 2026.

The immune-oncology drugs market is expected to generate a high revenue, owing to increasing introduction of new novel therapies for treatment of cancer with improved therapeutic outcomes that have led to increasing success rates against cancer. Novel immune therapies can restore the ability of immune system to identify and eliminate cancer cells, which is generally suppressed during course of cancer progression. Such immuno-oncology based therapies can be tailored to attack or block particular targets. For instance, Iplimumab, a human monoclonal antibody, which blocks cytotoxic T-lymphocyte-associated antigen-4 is available.

Cancer vaccines have also been developed such as Sipuleucel-T, Gardasil, and Cervarix. These vaccines either work as preventive vaccines or therapeutic vaccines. Adoptive cell transfer therapy is a new therapy emerging in the immuno-oncology such as CAR-T Cell Therapy, under which Kymriah and Yescarta are available.

Furthermore, organizations focusing on specific immune regulatory checkpoints such as programmed death-1 (PD-1) and programmed death ligand-1 and 2 (PD-L1) such as Nivolumab, Atezolimumab, and Pembrolizumab are being used for cell lung cancer. Monoclonal antibodies have been further developed into conjugated monoclonal antibodies, which are combined with other agents such as radiolabeled antibodies and chemo labeled antibodies.

India Immune-Oncology Drugs Market - Restraints

Major restraining factors for India immune-oncology drugs market include inadequate delivery of affordable and equitable cancer care drugs in India, which hampers the India immune-oncology drugs market. For instance, according to the data published in Lancet Journal in 2014, public expenditure on cancer in India remains below US$ 10 per person (compared to over US$ 100 per person in high-income or developed countries) and overall public expenditure on healthcare is still only slightly above 1% of the gross domestic product. According to the same source, out-of-pocket payments, which account for over three-quarter of cancer expenditures in India are one of the greatest threats to patients and families. Moreover, higher effectiveness of cancer drugs and comparatively less availability of better alternative results restricts key players to drive down cost of cancer drugs.

India Immune-Oncology Drugs Market Value (US$ Mn) & Y-o-Y Growth (%), 2018-2026

India Immune-Oncology Drugs  | Coherent Market Insights

 Source: Coherent Market Insights Analysis (2019)

India Immune-Oncology Drugs Market - Competitive Landscape

Key players operating in the India Immune-Oncology Drugs market include Amgen, Inc., F. Hoffmann-La Roche AG, Intas Pharmaceuticals Ltd., AstraZeneca plc, Mylan N.V., Dr. Reddy's Laboratories Ltd., Bristol - Myers Squibb, Merck & Co., Inc., BIOCAD-Biotechnology Company, Reliance Life Sciences, Biocon Limited, and Hetero Drugs Limited.

Immuno-Oncology refers to the use of body’s natural defenses to fight disease. It works by stimulating the immune system instead of fighting the tumors, avoiding disturbance in functionality of healthy cells. Immuno-oncology drugs facilitates long-term response against cancer by providing long-lasting memory to the immune system. Immuno-Oncology drugs works against a wide variety of cancers, which include non-small cell lung cancer, acute myeloid leukemia, lymphoma, multiple myeloma, breast cancer, and others. Immuno-oncology uses different types of cell-based immune therapies such as monoclonal antibodies, immune checkpoint inhibitors, cytokine-based immunotherapy, cancer vaccines, and other therapies. Commercially available immune-oncology therapies include Iplimumab, Nivolumab, Rituximab, Blinatumomab, Proleukin, Gardasil, and Kymriah.

Market Dynamics

Increasing prevalence of cancer in India is expected to drive India Immuno-Oncology Drugs market growth. For instance, according to National Cancer Registry Programme (NCRP), India, one woman dies of cervical cancer every 8 minutes in India. For every 2 women newly diagnosed with breast cancer, one woman dies of it in India. Furthermore, as many as 2,500 persons die every day due to tobacco-related diseases in India. Tobacco (smoked and smokeless) use accounted for around 317,928 deaths in men and women in 2018.

However, factors such as high-cost associated with immuno-oncology therapies makes it unaffordable for population in the low and middle-income class, to opt for these therapies, thus restraining growth of the market. For instance, Keytruda (Pembrolizumab), a monoclonal antibody for the treatment of various types of cancer costs around US$ 2,250 for a vial of 50 mg. Moreover, according to the World Health Organization (WHO), in February 2018, around 70% of deaths from cancer occur in low and middle-income countries. This can be attributed to high-prices of oncology therapies, which cannot be afforded by patients with low incomes.

Key features of the study:

  • This report provides in-depth analysis of the India immuno-oncology drugs market, market size (US$ Mn), and Compound Annual Growth Rate (CAGR (%)) for the forecast period: 2018 – 2026, considering 2017 as the base year
  • It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by leading players
  • It profiles key players in the India immuno-oncology drugs market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies
  • Key players covered as a part of this study include Amgen, Inc., F. Hoffmann-La Roche AG, Intas Pharmaceuticals Ltd., AstraZeneca plc, Mylan N.V., Dr. Reddy's Laboratories, Bristol - Myers Squibb, Merck & Co., Inc., BIOCAD-Biotechnology company, Reliance Life Sciences, Biocon Limited and Hetero Drugs Limited.
  • Insights from this report would allow marketers and management authorities of companies to make informed decision with respect to their future product launch, governmental initiatives, technological up-gradation, market expansion, and marketing tactics
  • India immuno-oncology drugs market report caters to various stakeholders in this industry, including investors, product manufacturers, distributors, and suppliers for India immuno-oncology drugs market, research and consulting firms, new entrants, and financial analysts

Detailed Segmentation:

  • India Immuno-Oncology Drugs Market, By Drug Type:
    • Immune Checkpoint Inhibitors
      • Nivolumab (Opdivo)
      • Atezolimumab (Tecentriq)
      • Pembrolizumab (Keytruda)
      • Durvalumab (Imfinzi)
    • Monoclonal Antibodies
      • Rituximab (Rituxan)
      • Trastazumab (Herceptin)
      • Bevacizumab (Avastin)
      • Nimotuzumab (Biomab EGFR)
      • Pertuzumab (Perjeta)
      • Ado-Trastuzumab Emtansine (Kadcyla)
    • Cancer Vaccines
      • Gardasil
      • Cervarix
  • India Immuno-Oncology Drugs Market, By Cancer Type:
    • Lung Cancer
    • Blood Cancer
    • Breast Cancer
    • Ovarian Cancer
    • Cervical Cancer
    • Colorectal Cancer
    • Stomach Cancer
    • Head & Neck Cancer
    • Others
  • Company Profiles
    • Amgen, Inc.*
      • Company Overview
      • Product Portfolio
      • Financial Performance
      • Recent Highlights
      • Strategies
    • Hoffmann-La Roche AG
    • Intas Pharmaceuticals Ltd.
    • AstraZeneca plc
    • Mylan N.V.
    • Reddy's Laboratories
    • Bristol - Myers Squibb
    • Merck & Co., Inc.
    • BIOCAD-Biotechnology company
    • Reliance Life Sciences
    • Biocon Limited
    • Hetero Drugs Limited

 “*” marked represents similar segmentation in other categories in the respective section.

Table of Contents

  1. Research Objective and Assumption
    • Research Objectives
    • Assumptions
    • Abbreviations
  2. Market Overview
    • Report Description
      • Market Definition and Scope
    • Executive Summary
      • Market Snippet, By Drug Type
      • Market Snippet, By Cancer Type
    • Coherent Opportunity Map (COM)
  3. Market Dynamics, Regulations, and Trends Analysis
    • Market Dynamics
      • Drivers
      • Restraints
      • Market Opportunities
    • Impact Analysis
    • Market Trends
    • Key Developments
    • Key Challenges
    • Regulatory Landscape
    • Patient Population
    • Epidemiology Analysis
    • PEST Analysis
    • Porter’s Five Forces model
  4. India Immuno-Oncology Drugs Market, By Drug Type, 2018 – 2026 , (US$ Million)
    • Introduction
      • Market Share Analysis, 2018 and 2026 (%)
      • Y-o-Y Growth Analysis, 2018 – 2026
      • Segment Trends
    • Immune Checkpoint Inhibitors
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2018 – 2026, (US$ Million)
        • Nivolumab
        • Atezolimumab
        • Pembrolizumab
        • Durvalumab
    • Monoclonal Antibodies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2018 – 2026, (US$ Million)
        • Rituximab
        • Trastazumab
        • Bevacizumab
        • Nimotuzumab
        • Pertuzumab
        • Ado-Trastuzumab Emtansine
    • Cancer Vaccines
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2018 – 2026, (US$ Million)
        • Gardasil
        • Cervarix
  5. India Immuno-Oncology Drugs Market, By Cancer Type, 2018 – 2026, (US$ Million)
    • Introduction
      • Market Share Analysis, 2018 and 2026 (%)
      • Y-o-Y Growth Analysis, 2018 – 2026
      • Segment Trends
    • Lung Cancer
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2018 – 2026, (US$ Million)
    • Blood Cancer
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2018 – 2026, (US$ Million)
    • Breast Cancer
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2018 – 2026, (US$ Million)
    • Ovarian Cancer
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2018 – 2026, (US$ Million)
    • Cervical Cancer
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2018 – 2026, (US$ Million)
    • Colorectal Cancer
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2018 – 2026, (US$ Million)
    • Stomach Cancer
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2018 – 2026, (US$ Million)
    • Head & Neck Cancer
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2018 – 2026, (US$ Million)
    • Other Cancers
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2018 – 2026, (US$ Million)
  6. Competitive Landscape
    • Company Profiles
      • Amgen, Inc.
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • F. Hoffmann-La Roche AG
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Intas Pharmaceuticals Ltd.
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • AstraZeneca plc
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Mylan N.V.
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Dr. Reddy's Laboratories
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Bristol-Myers Squibb
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Merck & Co., Inc.
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • BIOCAD-Biotechnology company
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Reliance Life Sciences
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Biocon Limited
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Hetero Drugs Limited
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
    • Analyst Views
  7. Section
    • References
    • Research Methodology
    • About Us and Sales Contact

*Browse 38 market data tables and 21 figures on "India Immuno-Oncology Drugs Market” - India forecast to 2026”

Choose License Type

"How Can I Help You" ?

Finding it difficult to find the research that would cater to your business demands? Give us a chance to help you. One of our Research Consultants will connect to provide a customized solution.

[email protected]

Key Benefits

  • Custom Research Solution

    Talk to our research consultant to design an exclusive report as per your research needs.

  • Customer Fulfilment

    We aim to fulfil client's research demands with tailored research solutions.

  • Quick Turnaround Time Reports

    We aim to provide research studies in quickest turnaround time and in a much cost effective manner.

  • 360-degree Approach

    We cover each industry from supply and demand side with an aim to provide a most holistic research study.

  • Assured Quality

    We strive to provide most accurate and reliable research findings in our research reports.